Trial Profile
A Phase I/II Study to Determine the MTD and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Antroquinonol (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Golden Biotechnology Corporation
- 22 Feb 2024 Planned End Date changed from 30 Dec 2023 to 31 Mar 2024.
- 20 Jan 2024 Results (n=55) assessing dose and efficacy of antroquinonol combined with gemcitabine and nab-paclitaxel (Gem/Nab-P) on mPC patients presented at the 2024 Gastrointestinal Cancers Symposium
- 18 Jan 2024 Results presented in the Golden Biotechnology Corporation Media Release.